Stipple Bio Secures $100 Million in Series A Funding
Stipple Bio, Inc., a biotechnology firm based in Cambridge, Massachusetts, has closed a $100 million Series A funding round. The company is focused on developing precision oncology therapies by leveraging its Pointillist Platform, which identifies tumor-specific cell surface epitopes.
Funding Details
The Series A round was co-led by RA Capital, a16z Bio+Health, and Nextech Invest. Other participants included Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners, and GordonMD Global Investments.
Leadership and Board Expansion
Aashish Manglik, Co-Founder of Stipple Bio, is at the helm of the company's efforts to bring precision-targeted cancer therapies to the market. Alongside the funding announcement, Stipple Bio also revealed that Derek DiRocco, PhD, and Thilo Schroeder, PhD, will join its Board of Directors. They will join current board members Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau, Aaron Ring MD, PhD, and Greg Ver.
Advancing Precision Oncology
Stipple Bio plans to use the funds to advance its lead candidate, STP-100, into early clinical studies by early 2027. STP-100 is an Antibody Drug Conjugate (ADC) designed to precisely target tumor cells while minimizing off-target effects, a common challenge in cancer treatment.
Strategic Use of Funds
The capital raised will primarily be used to advance the development of STP-100 and further expand Stipple Bio's precision oncology pipeline. The company aims to utilize its proprietary Pointillist Platform to enhance the therapeutic index of its cancer treatments.
With this significant infusion of funds, Stipple Bio is well-positioned to make strides in the field of precision oncology, potentially offering more effective and targeted treatment options for cancer patients in the near future.